Ahmedo Kaseb News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ahmedo kaseb. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ahmedo Kaseb Today - Breaking & Trending Today

Webinar Gives Hope for New Liver Cancer Treatments, Clinical Trial Improvements

A webinar presented by the Global Liver Institute highlighted areas of improvement needed in research for liver cancer, but also left listeners with hope for future treatments focused on strengthening immunity. ....

United States , Marka Mcniven , Bruno Sangro , Ahmedo Kaseb , Sarah Manes , University Of Texas Md Anderson Cancer Center , Md Anderson Cancer Center , Research In Liver Cancers , Global Liver Institute , National Cancer Institute , Specialized Programs Of Research Excellence , Global Liver Institute Tuesday , Advancing Research , Liver Institute , Cancer Center , Biomedical Discovery , Mayo Clinic , Clinica Universidad De Navarra , Global Liver , Specialized Programs , Research Excellence ,

Adjuvant Atezolizumab and Bevacizumab Delays Recurrence in Early-Stage HCC

Ahmed O. Kaseb, MD, discusses how the previous approval of atezolizumab and bevacizumab in hepatocellular carcinoma provided the impetus for the IMBrave050 study, how data from this study could support the regimen’s approval in the adjuvant setting, and how this approval could substantially improve the treatment landscape for early-stage disease. ....

United States , Roche Genentech , Ahmedo Kaseb , University Of Texas Md Anderson Cancer Center , Department Of Gastrointestinal Medical Oncology , Division Of Cancer Medicine , Bristol Myers Squibb , Gastrointestinal Medical Oncology , Cancer Medicine , Cancer Center , Hepatocellular Carcinoma , Gastrointestinal Cancer ,

Dr Kaseb on the Investigation of Adjuvant Atezolizumab and Bevacizumab in Early-Stage HCC

Ahmed O. Kaseb, MD, discusses the significance of results from the phase 3 IMbrave050 trial of adjuvant atezolizumab and bevacizumab for patients with early-stage hepatocellular carcinoma.

....

United States , Ahmedo Kaseb , University Of Texas Md Anderson Cancer Center , Department Of Gastrointestinal Medical Oncology , Division Of Cancer Medicine , Gastrointestinal Medical Oncology , Cancer Medicine , Cancer Center , 2023 Aacr Annual Meeting , Adjuvant Atezolizumab , Early Stage Hepatocellular Carcinoma , Phase 3 Imbrave050 Trial ,

Immunotherapy Treatment Shows Promise for Resectable Liver Cancer

Perioperative immunotherapy appears to be safe in the setting of resectable hepatocellular carcinoma, according to findings from an open-label phase 2 clinical trial. ....

United States , Ahmedo Kaseb , Bristol Myers Squibb , National Institutes Of Health , Md Anderson Cancer Center , Lancet Gastroenterology , Cancer Center , Nature Reviews , National Institutes , Hepatocellular Carcinoma , Liver Cancer , Hepatocellular Cancer , Ancer Liver , Ancer Hepatocellular , Biologic Therapy ,

Oncotarget: Treatment outcomes in patients with advanced hepatocellular carcinoma

The authors calculated the IGF/CTP score and used the Kaplan-Meier method and log-rank test to estimate and compare the time-to-event outcomes between patient subgroups.
171 patients were included, 116 of whom were CTP class A. Median PFS for IGF/CTP score AA and AB patients were 6.88 and 4.28 months, respectively.
Median OS for IGF/CTP score AA and AB patients were 14.54 and 7.60 months, respectively.
In CTP class A patients, IGF/CTP score B was associated with shorter PFS and OS, however, study was underpowered to reach statistical significance.
In CTP class A patients, IGF/CTP score B was associated with shorter PFS and OS ....

United States , Ahmedo Kaseb , University Of Texas Md Anderson Cancer Center , Kaseb Research Team , Cancer Center , Oncotargetresearch Output , ஒன்றுபட்டது மாநிலங்களில் , ஒலி கிளவுட் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் , புற்றுநோய் மையம் ,